Michael Thompson, MD PhD, completed his medical degree, a PhD in pharmacogenetics, and a residency in internal medicine, at the Mayo Clinic College of Medicine and Science in Rochester, MN. He then undertook a fellowship in hematology and oncology at the University of Texas MD Anderson Cancer Center in Houston, TX.
At present, Prof. Thompson is Co-Director of the Oncology Precision Medicine Program and the Medical Director of the Early Phase Cancer Research Program for Patient Centered Research at Aurora Health Care. Additionally, he is a Co-Principal Investigator of the National Cancer Institute Community Oncology Research program (NCIORP) and a Professor of Medicine at the University of Wisconsin-Madison.
Speaking on early phase trials for multiple myeloma and B-cell malignancies
Prof. Thompson is primarily involved in research on hematological malignancies such as lymphoma, myeloma, leukemia, and myelodysplastic syndrome (MDS). He is interested in the development of novel cancer treatments, specifically early phase molecular biomarker-driven studies.
Prof. Thompson has authored multiple papers exploring methods to improve the enrolment of patients on clinical trials. In addition, he frequently speaks on the importance of social media networks in oncology, and its role in engaging colleagues and educating patients.